-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gastroesophageal cancer, including esophageal adenocarcinoma (EAC), esophageal squamous cell carcinoma (ESCC), cardiac adenocarcinoma (GCA), and gastric non-cardiac adenocarcinoma (GNCA), is one of the deadliest cancers in the world
.
Barrett's esophagus is the only known precancerous lesion of EAC and GCA
Barrett's esophagus is the only known precancerous lesion of EAC and GCA
The aim of this study was to assess the risk of gastroesophageal cancer in patients with various histopathological abnormalities of the esophagus, including Barrett's esophagus
.
.
The researchers correlated histopathological data from esophageal biopsies obtained between 1979-2014 with several national population-based registries in Sweden
.
Patients were followed from 2 years after the date of the first biopsy until cancer, death, removal, esophagectomy/gastrectomy, or the end of follow-up (as of December 31, 2016)
During 831,394 person-years of follow-up, 367 cases of esophageal adenocarcinoma (EAC) were diagnosed
.
The incidence (IR) of EAC in individuals with normal morphology, inflammatory changes, and metaplastic changes on esophageal biopsy was 0.
The incidence (IR) of EAC in individuals with normal morphology, inflammatory changes, and metaplastic changes on esophageal biopsy was 0.
Cumulative incidence of esophageal cancer in different esophageal lesions
Cumulative incidence of esophageal cancer in different esophageal lesionsThe incidence of EAC in patients with atypical hyperplasia intestinal metaplasia was 1.
0/1000 person-years (95% CI 0.
7-1.
3), and the incidence rate of EAC in patients with non-dysplastic gastric/glandular metaplasia was 0.
9/1000 person-years Years (95%CI 0.
8-1.
1), the incidence of EAC in patients with low-grade dysplastic columnar metaplasia was 2.
9/1000 person-years (95%CI 2.
0-4.
2) ; the corresponding standardized incidence rates were 11.
7 ( 95%CI 8.
6-15.
5), 12.
0 (10.
0-14.
2) and 30.
2 (20.
5-42.
8)
.
There was a moderate increase in the standardized incidence of cardia adenocarcinoma (GCA)
The incidence of EAC in patients with atypical hyperplasia intestinal metaplasia was 1.
Patients with esophageal inflammation and other metaplastic abnormalities other than Barrett's esophagus also had a higher risk of EAC and GCA compared with the general population
Original source:
Original source:Ekheden, I.
leave a message here